- ￥2480
- EK-Bioscience
- CCC-Y1781
- 2025年07月16日
企业认证
相关产品推荐更多 >
万千商家帮你免费找货
0 人在求购买到急需产品
- 详细信息
- 文献和实验
- 技术资料
- 规格：
T25
SAS/SAS细胞系/SAS细胞株/SAS舌头鳞状肿瘤细胞
Cell line name SAS
Accession CVCL_1675
Resource Identification Initiative To cite this cell line use: SAS (RRID:CVCL_1675)
Comments Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).
Part of: COSMIC cell lines project.
Population: Japanese.
Doubling time: 33 hours (PubMed=24627082); ~30 hours (Note=Lot 07312007), ~21 hours (Note=Lot 08022016) (JCRB=JCRB0260).
Microsatellite instability: Stable (MSS) (Sanger).
Omics: CRISPR phenotypic screen.
Omics: Deep exome analysis.
Omics: Deep quantitative proteome analysis.
Omics: DNA methylation analysis.
Omics: SNP array analysis.
Omics: Transcriptome analysis by microarray.
Derived from site: In situ; Oral cavity, tongue; UBERON=UBERON_0001723.
Sequence variations
Mutation; HGNC; 11998; TP53; Simple; p.Glu336Ter (c.1006G>T); Zygosity=Homozygous (Cosmic-CLP=909708; DepMap=ACH-002029).
HLA typing Source: PubMed=9178645
Class I
HLA-A A*24
HLA-B B*52:01
HLA-C C*12:02
Genome ancestry Source: PubMed=30894373
Origin % genome
African 1.4
Native American 0
East Asian, North 79.62
East Asian, South 16.48
South Asian 1.04
European, North 0
European, South 1.46
Disease Tongue squamous cell carcinoma (NCIt: C4648)
Squamous cell carcinoma of the oral tongue (ORDO: Orphanet_457252)
Species of origin Homo sapiens (Human) (NCBI Taxonomy: 9606)
Hierarchy Children:
CVCL_R859 (SAS-H1) CVCL_R860 (SAS-L1) CVCL_A8GP (SAS-R)
Sex of cell Female
Age at sampling 69Y
Category Cancer cell line
STR profile Source(s): Cosmic-CLP=909708; DepMap=ACH-002029; JCRB=JCRB0260; RCB=RCB1974; TKG=TKG 0470
Markers:
Amelogenin X
CSF1PO 11
D3S1358 16,17
D5S818 9
D7S820 11,12
D8S1179 11,13
D13S317 10,12
D16S539 12,13
D18S51 15
D21S11 30
FGA 24
Penta D 10,13
Penta E 5,20
TH01 6,7
TPOX 11,12
vWA 10,14 (Cosmic-CLP=909708)
10,14,17 (JCRB=JCRB0260)
14,17 (DepMap=ACH-002029; RCB=RCB1974; TKG=TKG 0470)
Run an STR similarity search on this cell line
Publications
DOI=10.11277/stomatology1952.38.20
Takahashi K., Kanazawa H., Akiyama Y., Tazaki S., Takahara M., Muto T., Tanzawa H., Sato K.-i.
Establishment and characterization of a cell line (SAS) from poorly differentiated human squamous cell carcinoma of the tongue.
J. Jpn. Stomatol. Soc. 38:20-28(1989)
PubMed=9023415; DOI=10.1006/cimm.1996.1062
Seki N., Hoshino T., Kikuchi M., Hayashi A., Itoh K.
HLA-A locus-restricted and tumor-specific CTLs in tumor-infiltrating lymphocytes of patients with non-small cell lung cancer.
Cell. Immunol. 175:101-110(1997)
PubMed=9178645; DOI=10.1006/cimm.1997.1108
Nakao M., Sata M., Saitsu H., Yutani S., Kawamoto M., Kojiro M., Itoh K.
CD4+ hepatic cancer-specific cytotoxic T lymphocytes in patients with hepatocellular carcinoma.
Cell. Immunol. 177:176-181(1997)
PubMed=9290701; DOI=10.1002/(SICI)1098-2744(199708)19:4<243::AID-MC5>3.0.CO;2-D
Jia L.-Q., Osada M., Ishioka C., Gamo M., Ikawa S., Suzuki T., Shimodaira H., Niitani T., Kudo T., Akiyama M., Kimura N., Matsuo M., Mizusawa H., Tanaka N., Koyama H., Namba M., Kanamaru R., Kuroki T.
Screening the p53 status of human cell lines using a yeast functional assay.
Mol. Carcinog. 19:243-253(1997)
DOI=10.5843/jsot.13.Suppliment_301
Aida T., Irie T., Tachikawa T.
Establishment and charactalization of human oral squamous cell carcinoma cell line with highly lymph node metastatic potential.
J. Jpn. Soc. Oral Oncol. 13 Suppl. 1:301-306(2001)
PubMed=17325662; DOI=10.1038/sj.onc.1210330
Nakaya K., Yamagata H.D., Arita N., Nakashiro K.-i., Nose M., Miki T., Hamakawa H.
Identification of homozygous deletions of tumor suppressor gene FAT in oral cancer using CGH-array.
Oncogene 26:5300-5308(2007)
PubMed=20164919; DOI=10.1038/nature08768; PMCID=PMC3145113
Bignell G.R., Greenman C.D., Davies H.R., Butler A.P., Edkins S., Andrews J.M., Buck G., Chen L., Beare D., Latimer C., Widaa S., Hinton J., Fahey C., Fu B.-Y., Swamy S., Dalgliesh G.L., Teh B.T., Deloukas P., Yang F.-T., Campbell P.J., Futreal P.A., Stratton M.R.
Signatures of mutation and selection in the cancer genome.
Nature 463:893-898(2010)
PubMed=20215515; DOI=10.1158/0008-5472.CAN-09-3458; PMCID=PMC2881662
Rothenberg S.M., Mohapatra G., Rivera M.N., Winokur D., Greninger P., Nitta M., Sadow P.M., Sooriyakumar G., Brannigan B.W., Ulman M.J., Perera R.M., Wang R., Tam A., Ma X.-J., Erlander M., Sgroi D.C., Rocco J.W., Lingen M.W., Cohen E.E.W., Louis D.N., Settleman J., Haber D.A.
A genome-wide screen for microdeletions reveals disruption of polarity complex genes in diverse human cancers.
Cancer Res. 70:2158-2164(2010)
PubMed=24627082; DOI=10.3892/ijo.2014.2332
Fujinaga T., Kumamaru W., Sugiura T., Kobayashi Y., Ohyama Y., Ikari T., Onimaru M., Akimoto N., Jogo R., Mori Y.
Biological characterization and analysis of metastasis-related genes in cell lines derived from the primary lesion and lymph node metastasis of a squamous cell carcinoma arising in the mandibular gingiva.
Int. J. Oncol. 44:1614-1624(2014)
风险提示：丁香通仅作为第三方平台，为商家信息发布提供平台空间。用户咨询产品时请注意保护个人信息及财产安全，合理判断，谨慎选购商品，商家和用户对交易行为负责。对于医疗器械类产品，请先查证核实企业经营资质和医疗器械产品注册证情况。
文献和实验*发表【中文论文】请标注：由上海酶研生物科技有限公司提供；
*发表【英文论文】请标注：From Shanghai EK-Bioscience Biotechnology Co., Ltd.
Exploration of the underlying biological mechanisms of disease is useful for many purposes such as the development of novel treatment modalities in addition to informing on-going risk factor research. DNA-microarray technology is a relatively
细胞治疗是细胞和基因治疗的重要组成部分，它通过使用特定类型的细胞来修复、替换或调节受损的组织和器官。在细胞治疗中，不同类型的细胞因其独特的生物学特性而被广泛应用于多种疾病的治疗。以下是一些常用的细胞类型及其在细胞治疗中的应用。 （1）免疫细胞 免疫细胞是细胞治疗中最重要且研究最多的细胞类型之一，主要包括 T 细胞、自然杀伤细胞（NK 细胞）和树突状细胞（DC 细胞）。 T 细胞：T 细胞是人体免疫系统的核心细胞，具有强大的抗肿瘤能力。CAR-T 细胞疗法是目前最成功的免疫细胞治疗技术
简介 细胞增殖/细胞毒性测定是涉及培养细胞的研究中最常用的测试之一。 其是检查用于治疗的药物浓度的基本初步测试，也是确定各种研究领域（如肿瘤学和细胞死亡）药物疗效和安全性的非常重要的测试。 传统上，WST-8 或 ATP 检测（使用代谢活性作为指标）和 BrdU 或胸腺嘧啶核苷检测（使用 DNA 合成水平作为指标）已用于细胞生长特性的定量评估。 尽管这些检测由于其简易性和吞吐量而对我们有益，但这些检测都是间接评估方法，因此结果可能与实际细胞数无关。 在许多情况下，这些检测是终点评估，有时会
技术资料
